Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$317.77

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $317.77 13

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $317.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Xeris Pharmaceuticals, Inc. $111.8612/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946483565 CMS
Novo Nordisk Inc $17.2607/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898731519 CMS
Amgen Inc. $16.6703/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939271275 CMS
Novo Nordisk Inc $24.7803/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898905593 CMS
Mylan Specialty L.P. $15.5902/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963896071 CMS
Amneal Pharmaceuticals LLC $16.8802/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956585949 CMS
Novo Nordisk Inc $17.4502/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898855126 CMS
Novo Nordisk Inc $19.9102/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898629311 CMS
Currax Pharmaceuticals LLC $16.4102/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925770539 CMS
Merck Sharp & Dohme LLC $14.0202/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944775579 CMS
Janssen Pharmaceuticals, Inc $19.1102/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886017719 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.5102/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930058201 CMS
SANOFI-AVENTIS U.S. LLC $13.3201/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938751865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $662.27 12/31/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 826453479
Principal investigator 1 AstraZeneca UK Limited $2,351.14 12/31/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications No dispute reported 06/30/2026 826483883
Recipient Eli Lilly and Company $16.15 12/17/2021 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819445591
Principal investigator 1 ABBVIE INC. $2,077.05 12/16/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792487371
Principal investigator 1 Eli Lilly and Company $1,007.09 12/16/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819453951
Principal investigator 1 GRT US Holding, Inc. $8,500.00 12/16/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 839391209
Principal investigator 1 GRT US Holding, Inc. $1,500.00 12/16/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 839391211
Principal investigator 1 GRT US Holding, Inc. $1,500.00 12/16/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 839391213
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $6,500.00 12/14/2021 Non-covered Recipient Entity
Clinical Research Of W Fl
A double-blind randomized placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women No dispute reported 06/30/2026 821953529
Principal investigator 1 GlaxoSmithKline, LLC. $2,110.90 12/14/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 965539243
Principal investigator 1 SANOFI US SERVICES INC. $800.00 12/13/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667863
Principal investigator 2 UCB SA $5,000.00 12/13/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844230463
Principal investigator 2 UCB SA $3,700.00 12/13/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844230465
Principal investigator 1 ABBVIE INC. $2,807.10 11/30/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484457
Principal investigator 1 Eli Lilly and Company $15,000.00 11/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819454417
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 11/22/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667861
Principal investigator 2 UCB SA $34,674.00 11/08/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844231943
Principal investigator 1 ABBVIE INC. $3,151.06 11/04/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) No dispute reported 06/30/2026 792481431
Principal investigator 1 Beckman Coulter, Inc. $1,262.50 11/02/2021 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 844946762
Principal investigator 1 Beckman Coulter, Inc. $584.03 11/02/2021 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 844946775
Principal investigator 1 SANOFI US SERVICES INC. $4,150.00 11/02/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667851
Principal investigator 1 SANOFI US SERVICES INC. $611.00 11/02/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667853
Principal investigator 1 Eli Lilly and Company $561.92 10/26/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819455373
Principal investigator 1 ABBVIE INC. $4,045.10 10/14/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792479225
Principal investigator 1 UCB SA $55.73 10/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844227173
Principal investigator 2 UCB SA $52.44 10/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844227175
Recipient Eli Lilly and Company $1,678.03 10/08/2021 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819444981
Principal investigator 1 ABBVIE INC. $3,000.00 09/23/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792476279
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/20/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667843
Principal investigator 1 ABBVIE INC. $2,069.80 09/09/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792474875
Principal investigator 1 SANOFI US SERVICES INC. $10,125.00 08/16/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667829
Principal investigator 1 ABBVIE INC. $6,506.90 07/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792469905
Principal investigator 2 UCB SA $1,250.00 07/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844229675
Principal investigator 1 UCB SA $3,550.00 07/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844229677
Principal investigator 1 Beckman Coulter, Inc. $5,000.00 07/20/2021 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 844946751
Principal investigator 1 ABBVIE INC. $2,753.10 06/30/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792464923
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/25/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 838147725
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,500.00 06/25/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 838147729
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/25/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 838147733
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/25/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 838147737
Principal investigator 1 ABBVIE INC. $700.00 06/22/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792463675
Principal investigator 1 Abbott Laboratories $2,000.00 06/17/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Alinity m Resp-4-Plex Specimen Collection Protocol No dispute reported 06/30/2026 827569137
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,936.02 06/02/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147743
Principal investigator 1 ABBVIE INC. $3,305.10 06/01/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792461427
Principal investigator 1 Eli Lilly and Company $169,713.00 06/01/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819454271
Recipient Eli Lilly and Company $99.34 05/31/2021 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819445273
Principal investigator 1 UCB SA $1,143.24 05/20/2021 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF NEVADA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844231437
Principal investigator 1 Abbott Laboratories $100,116.00 05/07/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Alinity m Resp-4-Plex Specimen Collection Protocol No dispute reported 06/30/2026 827569135
Principal investigator 1 SANOFI US SERVICES INC. $13,500.00 05/04/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 838667791
Principal investigator 1 Eli Lilly and Company $49.67 04/30/2021 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819460739
Principal investigator 1 Eli Lilly and Company $49.67 04/30/2021 Non-covered Recipient Entity
WCCT GLOBAL LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819468585
Principal investigator 1 ABBVIE INC. $2,874.60 04/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792449563
Principal investigator 1 Eli Lilly and Company $21.90 04/28/2021 Non-covered Recipient Entity
JEFFREY B ROSEN MD PA DBA CLINICAL RESEARCH OF SOUTH
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819458571
Principal investigator 1 ABBVIE INC. $3,091.75 04/06/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792442737
Principal investigator 1 ABBVIE INC. $4,139.60 04/02/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792441983
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 04/01/2021 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147693
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.33 04/01/2021 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147697
Principal investigator 1 Abbott Laboratories $1,500.00 03/19/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Alinity m Resp-4-Plex Specimen Collection Protocol No dispute reported 06/30/2026 827569133
Principal investigator 1 Eli Lilly and Company $9,384.33 03/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 819454225
Principal investigator 1 UCB SA $1,000.00 03/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844223587
Principal investigator 1 UCB SA $1,250.00 03/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844223589
Principal investigator 1 UCB SA $3,250.00 03/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844223591
Principal investigator 1 Abbott Laboratories $4,500.00 03/03/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Alinity m Resp-4-Plex Specimen Collection Protocol No dispute reported 06/30/2026 827569131
Principal investigator 1 ABBVIE INC. $6,682.40 03/02/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792428687
Principal investigator 1 Beckman Coulter, Inc. $2,000.00 03/02/2021 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 844946741
Principal investigator 1 Abbott Laboratories $15,000.00 02/22/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Alinity m Resp-4-Plex Specimen Collection Protocol No dispute reported 06/30/2026 827569129
Principal investigator 1 UCB SA $4,603.21 02/18/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 844222989
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 02/17/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147681
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 02/17/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147685
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 02/17/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838147689
Principal investigator 1 Abbott Laboratories $114,581.25 02/08/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827569127
Principal investigator 1 AstraZeneca UK Limited $14,194.13 02/04/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications No dispute reported 06/30/2026 826478513
Principal investigator 1 Beckman Coulter, Inc. $3,000.00 02/02/2021 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 844946095
Principal investigator 1 ABBVIE INC. $7,085.70 01/28/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792415081
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,000.00 01/20/2021 Non-covered Recipient Entity
Clinical Research Of West Florida - Clearwater
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 819893015
Principal investigator 1 AstraZeneca UK Limited $1,671.07 01/19/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 826476217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,312.00 01/19/2021 Non-covered Recipient Entity
Clinical Research Of West Florida
Tio & Olo versus PBO stratified by PIFR No dispute reported 06/30/2026 840494239
Principal investigator 1 Abbott Laboratories $2,000.00 01/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827569121
Principal investigator 1 Abbott Laboratories $1,875.00 01/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827569123
Principal investigator 1 Abbott Laboratories $5,535.00 01/11/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827569125
Principal investigator 1 Novartis Pharmaceuticals Corporation $187,768.08 01/06/2021 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 800627729